Pourahmad Morteza, Tarrahi Mohammad Javad, Momenzadeh Mahnaz, Shahzamani Kiana, Jahromi Abdolreza Sotoodeh, Farajzadegan Ziba, Haghighipour Somayeh, Ataei Behrooz, Nikokar Fatemeh, Kakavand Nasim
Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Epidemiology and Biostatistics, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran.
BMC Infect Dis. 2025 Aug 18;25(1):1029. doi: 10.1186/s12879-025-11415-2.
Primary varicella-zoster virus (VZV) infection during pregnancy poses significant risks to both mother and fetus, including congenital varicella syndrome (CVS) and serious maternal complications. In Iran, the absence of varicella vaccination in the national immunization program leaves many women susceptible. This systematic review and meta-analysis aimed to determine the overall seroprevalence of VZV antibodies among reproductive-age women in Iran.
A comprehensive search was conducted in both international and Iranian databases for studies published up to November 15, 2024. Eligible studies reporting VZV seroprevalence among Iranian women aged 15-49 years were identified. Screening, data extraction, and risk of bias assessment were independently performed by two reviewers. Pooled seroprevalence was estimated using a random-effects meta-analysis in STATA version 18. Heterogeneity was evaluated with the Cochrane Q test and I² statistic. Subgroup analyses and meta-regression explored sources of heterogeneity. Sensitivity analyses (leave-one-out) and publication bias (Doi plot, LFK index) were also performed. The protocol was registered in PROSPERO (CRD42025647813).
Data from 20 studies, including 5,629 participants, were analyzed. A pooled VZV seroprevalence of 81% (95% CI: 77-85%) was found, indicating that approximately 19% of reproductive-age women in Iran remain susceptible. Higher seroprevalence was observed in pregnant women (88%) compared with non-pregnant women (79%), with the lowest rates among medical students (74%). Despite subgroup and meta-regression analyses, substantial heterogeneity remained unexplained. Sensitivity analyses supported the robustness of the results, while possible publication bias was suggested.
Nearly one in five reproductive-age women in Iran lack immunity to VZV. Targeted vaccination, especially among non-pregnant women and students, may reduce susceptibility. Preconception screening for VZV immunity could help prevent maternal and fetal complications. However, given the high unexplained heterogeneity, results should be interpreted with caution.
孕期原发性水痘-带状疱疹病毒(VZV)感染对母亲和胎儿均构成重大风险,包括先天性水痘综合征(CVS)和严重的母亲并发症。在伊朗,国家免疫规划中未纳入水痘疫苗接种,使得许多女性易受感染。本系统评价和荟萃分析旨在确定伊朗育龄妇女中VZV抗体的总体血清阳性率。
在国际和伊朗数据库中进行全面检索,查找截至2024年11月15日发表的研究。确定报告伊朗15至49岁女性VZV血清阳性率的合格研究。由两名 reviewers 独立进行筛选、数据提取和偏倚风险评估。使用STATA 18版中的随机效应荟萃分析估计合并血清阳性率。用Cochrane Q检验和I²统计量评估异质性。亚组分析和荟萃回归探讨异质性来源。还进行了敏感性分析(逐一剔除)和发表偏倚分析(Doi图、LFK指数)。该方案已在PROSPERO(CRD42025647813)注册。
分析了来自20项研究的数据,包括5629名参与者。发现合并的VZV血清阳性率为81%(95%CI:77 - 85%),表明伊朗约19%的育龄妇女仍易受感染。与非孕妇(79%)相比,孕妇的血清阳性率更高(88%),医学生中的血清阳性率最低(74%)。尽管进行了亚组分析和荟萃回归分析,但仍有大量异质性无法解释。敏感性分析支持结果的稳健性,同时提示可能存在发表偏倚。
伊朗近五分之一的育龄妇女缺乏对VZV的免疫力。有针对性的疫苗接种,尤其是在非孕妇和学生中,可能会降低易感性。孕前筛查VZV免疫力有助于预防母婴并发症。然而,鉴于存在高度无法解释的异质性,对结果的解释应谨慎。